STAVUDINE

US Previously Marketed

First approved in 1994

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

InChI

InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N

InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00649
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf

Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Stavudine is used for the treatment of human immunovirus (HIV) infections. Stavudine is sold under the brand name Zerit among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus 1 33 Target ID: CHEMBL378 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Inhibitor 8228		1.9 µM [IC50]
Human immunodeficiency virus type 1 reverse transcriptase 47 Target ID: CHEMBL247 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Inhibitor 8228		0.0083 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 150 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Primary		Approved 8360	Zerit Approved Use ZERIT (stavudine), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection Launch Date 7.7232957E11

C_max

Value	Dose	Co-administered	Analyte	Population
228 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
536 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1966 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2568 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Co-administed with:: didanosine(400 mg; 1/day) efavirenz(600 mg; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/	unhealthy, 36.5 n = 285 Health Status: unhealthy Condition: HIV-1 infection Age Group: 36.5 Sex: M+F Population Size: 285 Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/	Other AEs: Abdominal pain, Asthenia... Other AEs: Abdominal pain (19%) Asthenia (18%) Headache (25%) Diarrhea (34%) Dyspepsia (12%) Nausea (24%) Vomiting (12%) Lipodystrophy (6%) Arthralgia (6%) Myalgia (4%) Abnormal dreams (19%) Depressive disorders (13%) Dizziness (26%) Insomnia (22%) Neuropathy (13%) Paresthesia (12%) Cough increased (9%) Rhinitis (11%) Rash (35%) Skin discoloration (<1%) Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Co-administed with:: lamivudine indinavir Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult n = 100 Health Status: unhealthy Condition: HIV infection Age Group: adult Population Size: 100 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (43 patients) Diarrhea (34 patients) Headache (25 patients) Rash (18 patients) Vomiting (18 patients) Neuropathy peripheral (8 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Co-administed with:: didanosine indinavir Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult n = 102 Health Status: unhealthy Condition: HIV infection Age Group: adult Population Size: 102 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (53 patients) Diarrhea (45 patients) Headache (46 patients) Rash (30 patients) Vomiting (30 patients) Neuropathy peripheral (21 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult n = 412 Health Status: unhealthy Condition: HIV infection Age Group: adult Population Size: 412 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Headache, Diarrhea... Other AEs: Headache (54 patients) Diarrhea (50 patients) Neuropathy peripheral (52 patients) Rash (40 patients) Nausea and vomiting (39 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579	substrate 1010 inhibitor 1752	substrate 1193 inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 901 CYP2B6 799 CYP1A2 1509 CYP2A6 704 CYP2C19 1463 CYP2E1 876 BSEP 401 MRP2 367 MRP3 157 MRP4 203	CYP1A2 1032 CYP2C19 985 BCRP 555 P-gp 1527	P-gp 257

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 736	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1537	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 1875	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19	no [IC50 >10 uM]
CYP2E1 964	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 1909	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19	no [IC50 >10 uM]
BSEP 402	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 459	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 208	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 237	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2B6 985	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	unlikely
CYP2C8 955	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	weak
P-gp 1626	inducer 1542 Sources: https://pubmed.ncbi.nlm.nih.gov/18310046/	weak

Drug as victim

Target	Modality	Activity
CYP1A2 1032	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2C19 985	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2C9 1010	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
BCRP 555	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17202245/	yes
P-gp 1527	substrate 3326 Sources: https://www.sciencedirect.com/science/article/pii/S0024320510004005	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63581	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63581
ChemicalBook	CB4450928	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4450928
MolPort	MolPort-002-507-283	https://www.molport.com/shop/molecule-link/MolPort-002-507-283
ZINC	ZINC000000137884	http://zinc15.docking.org/substances/ZINC000000137884
eMolecules	536927	https://www.emolecules.com/cgi-bin/more?vid=536927
eMolecules	739264	https://www.emolecules.com/cgi-bin/more?vid=739264

PubMed

Title	Date	PubMed
Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV.	2001	11480491
Macrocytosis in patients on stavudine.	2001	11303821
[A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues].	2001 Apr	11373588
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.	2001 Apr	11306154
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1.	2001 Apr	11306153
Gynecomastia associated with highly active antiretroviral therapy.	2001 Apr	11302408
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.	2001 Apr	11264389
Treatment of hyperlipidemia in HIV-infected patients.	2001 Apr 1	11296612
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.	2001 Apr 13	11371699
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.	2001 Apr 13	11371696
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.	2001 Apr 13	11371686
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.	2001 Apr 13	11355843
R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.	2001 Apr 15	11391177
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.	2001 Apr 15	11304769
Antiviral drugs: current state of the art.	2001 Aug	11418355
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.	2001 Aug 1	11468426
Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response.	2001 Aug 1	11438909
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.	2001 Aug 15	11471110
Bristol-Myers warns of AIDS drugs' use.	2001 Feb	11279879
Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy.	2001 Feb 16	11273225
Gene mutations identified.	2001 Jan	11265651
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.	2001 Jan-Feb	11488127
New developments in anti-HIV chemotherapy.	2001 Jan-Feb	11347962
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.	2001 Jul	11486172
Predictors of protease inhibitor-associated adverse events.	2001 Jul	11478584
In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] (SAMPIDINE) in mice.	2001 Jul	11408371
Gynaecomastia in a male patient during stavudine and didanosine treatment for HIV infection.	2001 Jul	11394987
Stavudine versus zidovudine and the development of lipodystrophy.	2001 Jul 1	11464142
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.	2001 Jul 27	11504959
Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis.	2001 Jul-Aug	11485138
Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.	2001 Jun	11491422
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.	2001 Jun	11368826
Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.	2001 Jun 10	11429122
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).	2001 Jun 15	11372025
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.	2001 Jun 29	11442229
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.	2001 Jun 29	11319228
Peripheral neuropathy and antiretroviral drugs.	2001 Mar	11293802
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.	2001 Mar 30	11316999
Choosing which nuke to use first.	2001 May	11392690
Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice.	2001 May	11303038
Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.	2001 May 1	11404517
An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase.	2001 May 1	11319828
Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.	2001 May 25	11399997
Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.	2001 May 25	11399996
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.	2001 May 4	11399957
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.	2001 May 4	11399956
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.	2001 May 5	11356442
Warning for pregnant women on HIV therapy.	2001 May-Jun	11458554
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.	2001 Sep	11448730
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.	2001 Sep 14	11454872

Patents

Sample Use Guides

In Vivo Use Guide

Adults: The recommended dose based on body weight is as follows: 40 mg twice daily for patients ≥60 kg. 30 mg twice daily for patients <60 kg.

Route of Administration: Oral

In Vitro Use Guide

The concentration of Stavudine necessary to inhibit HIV-1 replication by 50% (EC50) ranged from 0.009 to 4 uM

Substance Class	Chemical Created by `admin` on `Thu Jul 06 21:35:42 UTC 2023` Edited by `admin` on `Thu Jul 06 21:35:42 UTC 2023`
Record UNII	BO9LE4QFZF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

STAVUDINE

Official Name

English

STAVUDINE [WHO-IP]

Common Name

English

STAVUDINE [MI]

Common Name

English

STAVUDINE [USAN]

Common Name

English

STAVUDINE (D4T) [VANDF]

Common Name

English

Stavudine [WHO-DD]

Common Name

English

ZERIT

Brand Name

English

D-4T

Code

English

STAVUDINE [USP MONOGRAPH]

Common Name

English

NSC-163661

Code

English

stavudine [INN]

Common Name

English

STAVUDINE [EP MONOGRAPH]

Common Name

English

SANILVUDINE

Common Name

English

THYMIDINE, 2',3'-DIDEHYDRO-3'-DEOXY-

Systematic Name

English

NSC-759897

Code

English

STAVUDINUM [WHO-IP LATIN]

Common Name

English

STAVUDINE [EMA EPAR]

Common Name

English

STAVUDINE [HSDB]

Common Name

English

ZIDOVUDINE IMPURITY A [WHO-IP]

Common Name

English

1-((2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE

Common Name

English

STAVUDINE [EP IMPURITY]

Common Name

English

STAVUDINE (DT4) [VANDF]

Common Name

English

STAVUDINE [ORANGE BOOK]

Common Name

English

STAVUDINE [MART.]

Common Name

English

1-(2,3-DIDEOXY-.BETA.-D-GLYCERO-PENT-2-ENOFURANOSYL)THYMINE

Common Name

English

ZIDOVUDINE IMPURITY A [EP IMPURITY]

Common Name

English

STAVUDINE [USP-RS]

Common Name

English

SANILVUDINE [JAN]

Common Name

English

D4T

Code

English

Classification Tree Code System Code

NDF-RT

N0000175462